ebola
viru
ebov
famili
filovirida
emerg
african
contin
sinc
caus
sever
outbreak
viral
hemorrhag
fever
human
case
fatal
rate
remain
seriou
public
health
concern
biothreat
pathogen
pathogen
beststudi
speci
zair
ebolaviru
zebov
ebov
encod
one
viral
surfac
glycoprotein
gp
essenti
replic
determin
pathogen
import
immunogen
gp
mediat
viral
entri
interact
cellular
surfac
molecul
result
uptak
viru
particl
via
macropinocytosi
later
pathway
endosom
acidif
activ
cystein
proteas
cathepsin
b
l
catb
catl
shown
cleav
zebovgp
lead
subsequ
exposur
put
receptorbind
fusion
domain
product
infect
studi
effect
catb
catl
vitro
vivo
replic
ebov
similar
previou
find
result
show
effect
catb
catl
zebov
entri
cultur
cell
interestingli
cell
entri
ebov
speci
bundibugyo
divoir
reston
sudan
ebolaviru
independ
catb
catl
ebov
replic
gener
investig
whether
catb
catl
role
vivo
infect
util
mous
model
zebov
wildtyp
control
catb
catl
mice
equal
suscept
lethal
challeng
mouseadapt
zebov
differ
viru
replic
time
death
conclus
result
show
catb
catl
activ
requir
ebov
replic
furthermor
ebov
glycoprotein
cleavag
seem
mediat
array
proteas
make
target
therapeut
approach
difficult
member
famili
filovirida
ebola
viru
ebov
marburg
viru
marv
caus
agent
viral
hemorrhag
fever
central
africa
major
public
health
threat
endem
area
worldwid
concern
relat
import
infect
individu
potenti
use
filovirus
biothreat
pathogen
current
marv
strain
belong
lake
victoria
marburgviru
speci
ebola
viru
ebov
strain
attribut
five
differ
speci
zair
ebolaviru
zebov
sudan
ebolaviru
sebov
divoir
ebolaviru
ciebov
reston
ebolaviru
rebov
bundibugyo
ebolaviru
bebov
speci
vari
pathogen
human
zebov
pathogen
case
fatal
rate
follow
sebov
bebov
case
fatal
rate
respect
ciebov
rebov
caus
lethal
infect
nonhuman
primat
yet
associ
fatal
human
case
although
ebov
mainli
zebov
marv
extens
studi
vitro
vivo
today
neither
licens
vaccin
treatment
avail
ebov
entri
target
cell
still
fulli
understood
remain
focu
ongo
research
number
attach
factor
seem
facilit
ebov
entri
far
specif
cell
surfac
receptor
molecul
identifi
recent
shown
cholesterol
transport
niemannpick
requir
zebov
infect
ubiquit
express
endosom
membran
protein
involv
fusion
fission
endosom
lysosom
defici
shown
impact
particl
releas
presenc
endosom
fit
current
ebov
entri
model
base
macropinocytosi
cellular
pathway
propos
main
uptak
mechan
ebov
particl
cell
previous
chandran
et
al
identifi
cystein
proteas
cathepsin
b
catb
cathepsin
l
catl
also
present
endosom
import
factor
zebov
entri
accord
current
model
cleavag
zebov
glycoprotein
gp
catb
necessari
exposur
core
receptorbind
domain
fusion
machineri
otherwis
buri
gp
structur
initi
fusion
viral
endosom
membran
subsequ
viral
genom
along
replic
complex
releas
cytoplasm
replic
viru
progeni
product
occur
catb
catl
member
famili
human
cystein
proteas
proteas
highli
abund
broadli
express
exhibit
nonspecif
proteolyt
activ
within
lysosom
catb
associ
tnfa
induc
liver
damag
seem
play
critic
role
develop
pancreat
despit
fact
catb
mice
phenotyp
similar
wildtyp
control
mice
fulli
immunocompet
catl
import
epiderm
homeostasi
regul
hair
cycl
catl
mice
hairless
furthermor
catl
involv
mhc
iimedi
antigen
present
epitheli
cell
thymu
consequ
catl
mice
reduc
number
helper
cell
howev
fulli
function
doubl
knockout
mous
lack
catb
catl
gener
viabl
long
enough
experiment
use
determin
import
cathepsin
viral
infect
variou
inhibitor
endosom
acidif
cathepsin
specif
catb
catl
activ
use
vitro
studi
role
cathepsin
demonstr
import
entri
reoviru
sarscov
henipavirus
zebov
show
catb
mediat
zebov
entri
vitro
import
entri
replic
ebov
speci
show
vivo
replic
mouseadapt
zebov
mazebov
independ
catb
catl
indic
cathepsin
requir
zebov
replic
vivo
anim
handl
biosafeti
level
contain
space
integr
research
facil
irf
rocki
mountain
laboratori
rml
divis
intramur
research
dir
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
research
conduct
complianc
guidelin
niaid
rml
institut
anim
care
use
committe
iacuc
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
aaalac
approv
offic
laboratori
anim
welfar
olaw
assur
research
conduct
protocol
approv
iacuc
procedur
conduct
train
personnel
veterinari
supervis
invas
clinic
procedur
perform
anim
anesthet
endpoint
criteria
specifi
iacuc
approv
score
paramet
use
determin
anim
human
euthan
vero
cell
mous
embryon
fibroblast
mef
cell
line
lack
cathepsin
b
cathepsin
l
cathepsin
cultur
dulbecco
modifi
eagl
medium
dmem
sigma
st
loui
mo
supplement
fb
penicillinstreptomycin
lglutamin
incub
co
vsv
serotyp
indiana
sar
strain
tor
bebov
ciebov
strain
tai
forest
rebov
strain
pennsylvania
sebov
strain
bonifac
zebov
strain
mayinga
furin
knockout
mouseadapt
variant
zebov
zebovfko
mazebov
respect
propag
vero
cell
supernat
clear
cell
debri
centrifug
min
aliquot
store
liquid
nitrogen
viral
titer
determin
conduct
convent
plaqu
assay
immunoplaqu
assay
infecti
work
ebov
perform
biosafeti
level
laboratori
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
irf
rml
dir
niaid
nih
endosom
acidif
inhibitor
bafilomycin
inhibitor
specif
catb
obtain
sigma
st
loui
mo
catlinhibitor
v
purchas
calbiochem
via
emd
chemic
inc
gibbstown
nj
inhibitor
dissolv
dmso
store
dilut
prepar
plain
dmem
supplement
prior
everi
experi
foci
reduct
experi
vero
cell
seed
plate
day
infect
media
remov
cell
incub
one
hour
ml
inhibitor
follow
concentr
describ
previous
nm
catb
mm
catlinhibitor
v
mm
ml
plain
dmem
focu
form
unit
ffu
viru
ad
kept
one
hour
three
wash
plain
dmem
mixtur
carboxymethyl
cellulos
cmc
minim
essenti
medium
mem
life
technolog
carlsbad
ca
supplement
fb
penicillinstreptomycin
lglutamin
ad
contain
appropri
concentr
inhibitor
nm
catb
mm
catlinhibitor
v
mm
sar
infect
cell
fix
stain
crystal
violet
plaqu
count
three
day
infect
four
day
infect
ebov
inocul
cell
fix
neutral
buffer
formalin
remov
follow
standard
oper
procedur
subsequ
cell
permeabil
foci
stain
rabbit
antibodi
kindli
provid
kawaoka
univers
wisconsin
madison
wi
rabbit
serum
direct
rebovnp
kindli
provid
takada
hokkaido
univers
sapporo
japan
follow
fitclabel
secondari
antibodi
sigma
st
loui
mo
foci
count
use
fluoresc
microscop
carl
zeiss
microimag
llc
thornwood
ny
vero
cell
seed
plate
day
experi
pretreat
occur
ml
nm
mm
mm
catlinhibitor
v
inhibitor
hour
thereaft
ml
zebovwt
moi
ad
cell
incub
anoth
hour
follow
three
wash
current
believ
ebola
viru
ebov
enter
cell
via
macropinocytosi
follow
cystein
proteas
cathepsin
b
l
catb
catl
cleav
viral
glycoprotein
gp
allow
exposur
core
receptorbind
fusion
domain
thu
facilit
subsequ
infect
studi
effect
catb
catl
vitro
vivo
ebov
replic
result
demonstr
reduct
zair
ebolaviru
zebov
entri
upon
select
inhibit
catb
catl
cell
cultur
interestingli
ebov
speci
enter
cell
effici
catb
andor
catl
activ
block
moreov
wildtyp
control
catb
catl
mice
infect
lethal
dose
mouseadapt
zebov
anim
equal
suscept
lethal
challeng
differ
viru
replic
time
death
therefor
conclud
ebov
replic
dispens
catb
catl
proteolyt
process
gp
also
mediat
endosom
proteas
plain
dmem
cell
well
cover
ml
dmem
supplement
fb
contain
nm
mm
mm
catlinhibitor
v
inhibitor
mef
cell
line
seed
plate
day
experi
infect
ml
zebovwt
mazebov
moi
ad
incub
one
hour
follow
three
wash
plain
dmem
cell
well
cover
ml
dmem
supplement
fb
time
point
hour
post
infect
ml
supernat
collect
infect
cell
ml
dmem
fb
contain
appropri
concentr
inhibitor
ad
back
well
sampl
store
titrat
vero
cell
group
catb
catl
control
mice
infect
intraperiton
ip
ffu
mazebov
ld
pfu
vsvwt
serotyp
indiana
monitor
daili
weight
loss
sign
diseas
day
post
infect
mice
group
euthan
blood
liver
spleen
sampl
collect
store
viru
titrat
surviv
anim
euthan
day
studi
endpoint
final
serum
collect
determin
antibodi
titer
vero
cell
seed
plate
day
titrat
liver
spleen
sampl
thaw
weigh
homogen
weightvolum
plain
dmem
serial
dilut
prepar
blood
sampl
supernat
collect
infect
cell
determin
viral
growth
zebovwt
mazebov
thaw
serial
dilut
prepar
media
remov
cell
triplic
inocul
dilut
one
hour
dmem
supplement
fb
penicillinstreptomycin
lglutamin
ad
incub
cell
monitor
cytopath
effect
cpe
tissu
cultur
infecti
dose
tcid
calcul
sampl
employ
reed
muench
method
detect
zebovgp
specif
antibodi
mous
sera
solubl
zebovgp
antigen
zebovgpdtm
produc
use
enzymelink
immunosorb
assay
elisa
describ
detect
vsvspecif
antibodi
vsv
propag
vero
cell
vsv
particl
harvest
hr
purifi
centrifug
sucros
cushion
treat
pb
prior
storag
elisa
use
vsv
antigen
dilut
sera
mice
infect
mazebov
inactiv
cirradi
per
standard
oper
protocol
oneway
anova
perform
use
prism
graph
pad
softwar
inc
observ
entri
zebov
vero
cell
catband
catldepend
initi
describ
chandran
colleagu
analysi
zebov
uptak
vero
cell
perform
differ
vitro
assay
base
foci
reduct
use
inhibitor
cell
seed
treat
variou
lysosom
cathepsin
inhibitor
one
hour
infect
zebov
wildtyp
wt
one
hour
cover
carboxymethyl
cellulos
contain
inhibitor
fix
incub
day
number
foci
determin
immunostain
inhibit
catb
result
significantli
reduc
viru
entri
wherea
catl
proteolyt
activ
appear
obligatori
zebov
uptak
vero
cell
although
catl
highli
express
cell
sarscov
use
catldepend
control
viru
verifi
activ
catl
inhibitor
fig
addit
zebovwt
also
test
furin
cleavag
site
knockout
zebov
zebovfko
mazebov
assay
determin
whether
furin
cleavag
glycoprotein
mutat
caus
adapt
process
viru
mice
would
influenc
requir
cathepsin
cleavag
virus
enter
vero
cell
catbdepend
manner
similar
zebovwt
affect
presenc
catl
inhibitor
fig
result
show
uptak
test
virus
occur
util
cellular
endocytoti
machineri
indic
inhibitori
effect
bafilomycin
endosom
acidif
inhibitor
furthermor
proteolyt
process
zebovgp
furin
prerequisit
cathepsin
cleavag
viru
matur
entri
process
addit
mutat
throughout
viral
genom
acquir
adapt
process
zebov
mous
influenc
zebov
uptak
data
zebov
partial
support
previous
publish
observ
confirm
recent
studi
claim
catb
rather
catl
play
role
zebov
entri
therefor
studi
role
cathepsin
cleavag
viru
entri
bebov
ciebov
rebov
sebov
use
repres
strain
ebov
speci
foci
reduct
assay
perform
evalu
describ
infect
virus
reduc
presenc
fig
confirm
endosom
acidif
play
critic
role
entri
process
ebov
interestingli
maximum
concentr
catb
inhibitor
effect
bebov
uptak
vero
cell
wherea
ciebov
rebov
sebov
produc
foci
independ
presenc
inhibitor
fig
entri
none
ebov
affect
catl
inhibitor
data
suggest
catb
equal
import
entri
ebov
seem
select
effect
zebov
limit
effect
bebov
entri
confirm
catb
role
zebov
entri
analyz
viru
replic
presenc
cathepsin
inhibitor
vero
cell
treat
inhibitor
nm
catb
mm
catl
mm
one
hour
prior
zebovwt
infect
moi
unbound
viru
wash
away
cell
cover
medium
contain
inhibitor
nm
catb
mm
catl
mm
sampl
taken
indic
time
point
store
viru
titrat
viru
titer
determin
vero
cell
use
tissu
cultur
infecti
dose
tcid
assay
calcul
use
reed
muench
formula
fig
result
demonstr
zebov
replic
similar
titer
presenc
catb
catl
inhibitor
differ
less
log
presenc
inhibitor
reduc
zebov
replic
log
indic
catb
inhibitori
effect
entri
like
compens
cellular
proteas
howev
reduc
viru
growth
log
show
endosom
acidif
import
effici
zebov
entri
replic
fig
order
confirm
data
perform
zebovwt
mazebov
infect
mef
cell
line
defici
express
catb
catl
cathepsin
cell
infect
one
hour
zebovwt
mazebov
moi
sampl
taken
indic
time
point
viru
titer
determin
vero
cell
use
tcid
assay
calcul
use
reed
muench
formula
fig
c
zebovwt
mazebov
replic
similarli
well
absenc
catb
catl
proteas
although
small
differ
titer
observ
certain
time
point
oneway
anova
find
statist
signific
p
valu
fig
catb
catl
mice
succumb
zebov
infect
final
vitro
data
verifi
vivo
use
wellestablish
lethal
mous
model
zebov
catb
catl
mice
well
character
therefor
ideal
determin
import
catb
catl
zebov
replic
vivo
mef
cell
line
obtain
mice
use
previou
studi
demonstr
mous
cathepsin
function
similar
human
cathepsin
import
zebovgpmedi
entri
group
catb
catl
control
mice
infect
ld
mazebov
monitor
daili
sign
diseas
includ
weight
loss
fig
b
day
postinfect
mice
group
euthan
blood
liver
spleen
sampl
taken
determin
viral
load
fig
anim
catl
group
succumb
mazebov
infect
day
similar
control
mice
one
catb
mice
challeng
mazebov
succumb
infect
one
surviv
mous
show
sign
diseas
recov
fig
b
previous
observ
infect
control
mice
alway
uniformli
lethal
control
mice
develop
diseas
surviv
challeng
fig
b
signific
differ
viral
titer
liver
spleen
blood
sampl
taken
day
post
mazebov
infect
three
differ
mous
strain
fig
day
post
mazebov
infect
liver
spleen
titer
similar
among
three
mous
strain
higher
blood
catb
catl
mice
compar
wt
mice
fig
indic
diseas
progress
outcom
similar
anim
fig
order
exclud
occurr
mutat
glycoprotein
gp
gene
mazebov
vivo
replic
determin
full
gp
sequenc
found
mutat
data
shown
exclud
catb
catl
mice
gener
suscept
viral
infect
group
mice
infect
recombin
vesicular
stomat
viru
vsv
strain
indiana
monitor
daili
weight
loss
sign
ill
fig
vsv
caus
diseas
mice
demonstr
neither
catb
catl
mice
possess
increas
suscept
viru
infect
blood
liver
spleen
sampl
one
hour
prior
infect
cell
incub
inhibitor
direct
indic
cathepsin
endosom
acidif
baf
zebovwt
ad
moi
incub
one
hour
three
wash
cell
cover
ml
medium
contain
nm
mm
mm
catl
inhibitor
v
inhibitor
incub
day
b
c
mef
cell
line
seed
night
taken
day
post
vsv
infect
viral
rna
detect
data
shown
indic
catb
catl
well
control
mice
abl
effici
clear
viru
elisa
perform
serum
sampl
mice
show
anim
infect
indic
detect
vsvspecif
antibodi
fig
data
demonstr
obviou
differ
catb
catl
control
mice
suscept
viral
infect
develop
immun
respons
present
studi
demonstr
catb
catl
mediat
zebov
uptak
vero
cell
observ
partial
line
initi
vitro
studi
demonstr
catb
catl
depend
uptak
zebov
support
recent
studi
show
catb
mediat
zebov
entri
target
cell
addit
could
demonstr
posttransl
furin
cleavag
zebovgp
fragment
gp
gp
prerequisit
cathepsin
process
result
come
big
surpris
consid
earlier
studi
report
zebov
replic
pathogen
independ
furin
cleavag
interestingli
ebov
speci
test
studi
seem
enter
vero
cell
catband
catlindepend
manner
suggest
endosom
proteas
might
function
replac
catb
viru
entri
find
disagr
recent
publish
data
show
cell
entri
vsvand
pseudotyp
particl
express
differ
ebovgp
catbdepend
interestingli
one
studi
also
show
cell
entri
infecti
sebov
strain
gulu
catband
catlindepend
could
demonstr
infect
cell
infect
hour
ml
zebovwt
b
mazebov
c
moi
three
wash
cell
cover
ml
medium
incub
day
experi
sampl
collect
hour
post
infect
infecti
titer
determin
repres
experi
perform
triplic
shown
error
bar
indic
standard
error
mean
differ
sebov
strain
strain
bonifac
discrep
among
data
previous
publish
report
might
explain
differ
size
shape
particl
well
mechan
particl
uptak
particl
larg
spheric
mechan
uptak
receptor
mediat
interact
surfac
glycoprotein
vsv
particl
short
bulletshap
cell
uptak
occur
via
endocyt
pathway
infecti
zebov
context
interact
gp
miss
pseudotyp
particl
may
influenc
cellular
uptak
mechan
altogeth
suggest
vsvbase
pseudotyp
particl
entri
could
differ
filoviru
particl
extrem
long
filament
shape
mainli
util
macropinocytosi
particl
uptak
addit
ciebovgp
use
produc
vsvbase
pseudotyp
particl
one
studi
lack
mucinlik
domain
could
impact
gp
structur
thu
might
affect
cleavag
entri
view
highlight
need
confirm
data
obtain
pseudotyp
particl
system
live
ebov
infect
least
use
ebovlik
particl
final
cell
type
origin
may
also
influenc
catband
catlmedi
cleavag
studi
perform
differ
cell
line
sarscov
entri
report
highli
catldepend
shown
express
cellular
transmembran
proteas
serin
overcom
block
sarscov
infect
replic
caus
catl
inhibitor
moreov
signal
tolllik
receptor
initi
associ
catb
catl
catk
activ
howev
studi
use
bone
marrow
deriv
macrophag
dendrit
cell
deriv
cathepsin
knockout
mice
identifi
singl
cathepsin
essenti
factor
signal
rather
point
toward
role
endolysosom
proteas
asparagin
endopeptidas
aep
activ
thu
seem
reason
specul
absenc
catb
catl
correspond
knockout
mice
endosom
proteas
mediat
ebovgp
cleavag
enabl
cathepsinindepend
ebov
entri
target
cell
previou
report
shown
ebovgp
also
process
cathepsin
mef
indic
mous
catb
catl
function
activ
demonstr
similarli
zebovwt
cell
entri
mazebov
vero
cell
catbdepend
catlindepend
fig
furthermor
ebov
replic
high
titer
mef
cell
line
independ
catb
andor
catl
fig
c
therefor
use
mous
diseas
model
investig
effect
cathepsin
zebov
replic
vivo
mice
genet
background
catb
catl
knockout
mice
catb
catl
show
increas
suscept
viral
infect
gener
determin
vsv
fig
contrast
knockout
mice
infect
mazebov
succumb
infect
differ
diseas
progress
time
death
fig
viral
load
liver
spleen
blood
fig
demonstr
mazebov
replic
vivo
catband
catlindepend
conclus
studi
indic
catb
catl
absolut
requir
ebov
replic
yet
unknown
reason
catb
seem
play
consider
role
zebov
uptak
ebov
speci
ebov
seem
evolv
use
broader
spectrum
endosom
proteas
ensur
gp
cleavag
thu
facilit
success
infect
target
cell
therefor
therapeut
approach
target
singl
proteas
unlik
benefici
combat
ebov
infect
